TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22825942

Group type: EXPERIMENTAL
Intervention: BMI ≥ 25 kg/m(2)
Number of subjects: 131

Group type: COMPARATOR
Intervention: BMI < 25 kg/m(2)
Number of subjects: 131
Study: 20526599

Group type: EXPERIMENTAL
Intervention: Alvimopan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18388765

Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT-BN)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Individual supportive psychotherapy
Number of subjects: 80
Study: 16497254

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 12559536

Group type: EXPERIMENTAL
Intervention: Amiodarone and verapamil 240 mg/day (group VER)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Amiodarone and metoprolol 100 mg/day (group MET)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Only amiodarone (group AMI)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (n=13)
Number of subjects: 21
Study: 10828223

Group type: EXPERIMENTAL
Intervention: Prostar Plus (PVS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional manual compression
Number of subjects: 60
Study: 9083316

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol, 50 microg every 4 hours up to three doses (n = 76)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Intracervical dinoprostone gel, 0.5 mg every 6 hours up to three doses (n = 79)
Number of subjects: 155
Study: 8472213

Group type: EXPERIMENTAL
Intervention: He:Ne laser treatment
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: He:Ne + Nd:YAG laser treatment
Number of subjects: 19
Study: 2992300

Group type: EXPERIMENTAL
Intervention: Naltrexone administration
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 30873586

Group type: EXPERIMENTAL
Intervention: Ego depletion manipulations
Number of subjects: 0
Study: 30996056

Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 667

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 667
Study: 27753111

Group type: EXPERIMENTAL
Intervention: HyFoSy (foam instillation)
Number of subjects: 37

Group type: COMPARATOR
Intervention: HyCoSy (saline solution)
Number of subjects: 37
Study: 25452017

Group type: EXPERIMENTAL
Intervention: Stabilization treatment
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Movement system impairment-based treatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (subjects without LBP)
Number of subjects: 33
Study: 23356115

Group type: EXPERIMENTAL
Intervention: CRIC device
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard surgical method
Number of subjects: 20
Study: 21493422

Group type: EXPERIMENTAL
Intervention: Pillar implants
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 51
Study: 19660037

Group type: EXPERIMENTAL
Intervention: Surgical debridement
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Frequent debridement
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Serial debridement in DFUs
Number of subjects: 676

Group type: COMPARATOR
Intervention: No surgical debridement
Number of subjects: 676
Study: 16918655

Group type: EXPERIMENTAL
Intervention: Pediatric heat and moisture exchange filter (HMEF)
Number of subjects: 10
Study: 15806263

Group type: EXPERIMENTAL
Intervention: Bilateral arciform incision
Number of subjects: 20

Group type: COMPARATOR
Intervention: Supra-umbilical midline incision
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 20
Study: 11371405

Group type: EXPERIMENTAL
Intervention: Pulmonary edema fluid from patients with ALI/ARDS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pooled plasma from healthy donors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist
Number of subjects: 0
Study: 9296429

Group type: EXPERIMENTAL
Intervention: Topical 60% lidocaine tape (Group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine mixed with propofol (Group C)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Bioocclusive dressing with propofol (Group A)
Number of subjects: 90
Study: 8359191

Group type: EXPERIMENTAL
Intervention: Nocloprost 5 micrograms i.v.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nocloprost 100, 200, and 400 micrograms p.o.
Number of subjects: 10
Study: 3535752

Group type: EXPERIMENTAL
Intervention: alpha-2 interferon (2 X 10(6) IU, three times each week for up to 52 weeks)
Number of subjects: 98

Group type: COMPARATOR
Intervention: placebo (three times each week for up to 52 weeks)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: alpha-2 interferon
Number of subjects: 98

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 98
Study: 31505892

Group type: EXPERIMENTAL
Intervention: PM education group (pattern management education using continuous glucose monitoring system results)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (traditional diabetes education)
Number of subjects: 0
Study: 29972942

Group type: EXPERIMENTAL
Intervention: Graft group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-graft group
Number of subjects: 30
Study: 26664107

Group type: EXPERIMENTAL
Intervention: COPD cases identified by spirometry
Number of subjects: 5463

Group type: COMPARATOR
Intervention: Healthy subjects (controls)
Number of subjects: 5463

Group type: EXPERIMENTAL
Intervention: Univariate logistic regression analysis
Number of subjects: 5463

Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression model
Number of subjects: 5463

Group type: EXPERIMENTAL
Intervention: Protective factors identified
Number of subjects: 5463
Study: 23683374

Group type: EXPERIMENTAL
Intervention: Resistance training + diet (RT+diet); n=4
Number of subjects: 7

Group type: COMPARATOR
Intervention: Diet control; n=3
Number of subjects: 7
Study: 22011335

Group type: EXPERIMENTAL
Intervention: Swaymeter
Number of subjects: 40
Study: 19926008

Group type: EXPERIMENTAL
Intervention: Amlodipine, Lisinopril, Doxazosin
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Baseline AF/AFL
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: AF/AFL presence at baseline or during trial
Number of subjects: 423
Study: 17166343

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 0

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 0
Study: 14719298

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment using the eight methods of intelligent turtle (Ling Gui Ba Fa)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group treated with points selected according to syndrome-differentiation
Number of subjects: 0
Study: 10802401

Group type: COMPARATOR
Intervention: Alora placebo patch
Number of subjects: 99
Study: 8880096

Group type: EXPERIMENTAL
Intervention: Flumazenil (2 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 10
Study: 2000035

Group type: EXPERIMENTAL
Intervention: 250 mg/kg body weight (BW) protein meal
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 500 mg/kg BW protein meal
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1 g/kg BW protein meal
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 2 g/kg BW protein meal
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All protein meals
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 250 mg/kg BW protein meal
Number of subjects: 8
Study: 6408500

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 70
Study: 31002434

Group type: EXPERIMENTAL
Intervention: mAFA-integrated care intervention
Number of subjects: 3660

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3660
Study: 29215514

Group type: EXPERIMENTAL
Intervention: Misoprostol with transcervical Foley bulb
Number of subjects: 200

Group type: COMPARATOR
Intervention: Misoprostol alone
Number of subjects: 200
Study: 27111273

Group type: EXPERIMENTAL
Intervention: Partially hydrolysed whey formula containing oligosaccharides (0.8 g/100 ml) (pHF‐OS)
Number of subjects: 863

Group type: COMPARATOR
Intervention: Standard cow's milk formula (control)
Number of subjects: 863

Group type: EXPERIMENTAL
Intervention: Partially hydrolysed whey formula containing oligosaccharides (pHF‐OS)
Number of subjects: 863
Study: 25482837

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: aripiprazole
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: olanzapine
Number of subjects: 600
Study: 22252800

Group type: EXPERIMENTAL
Intervention: Primaquine plus chloroquine (3 days)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Primaquine plus artesunate (7 days)
Number of subjects: 393
Study: 21375020

Group type: EXPERIMENTAL
Intervention: Acupuncture group
Number of subjects: 92

Group type: COMPARATOR
Intervention: Medication group
Number of subjects: 92
Study: 18062596

Group type: EXPERIMENTAL
Intervention: Early surgery (microdiscectomy after a mean of 2.2 weeks)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Conservative treatment (prolonged conservative treatment with later surgery if necessary)
Number of subjects: 283
Study: 16130059

Group type: EXPERIMENTAL
Intervention: Ketamine anesthesia (IV ketamine 1 to 2 mg/kg, fentanyl 1 to 2 microg/kg, maintained with ketamine 25 to 75 microg/kg/min and fentanyl 10 microg/kg/h)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Isoflurane anesthesia (IV thiopental sodium 3 to 5 mg/kg, fentanyl 1 to 2 microg/kg, maintained with 1% isoflurane and fentanyl 10 microg/kg/h)
Number of subjects: 34
Study: 12153124

Group type: EXPERIMENTAL
Intervention: Judgments about the Latina woman
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Judgments about the Anglo-Saxon and Jewish women
Number of subjects: 0
Study: 10487074

Group type: EXPERIMENTAL
Intervention: RGP contact lenses worn for about 8 hours a day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: RGP contact lenses
Number of subjects: 100

Group type: COMPARATOR
Intervention: Spectacles
Number of subjects: 100
Study: 8757425

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) 1,000 mg alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) 500 mg + low-dose interferon-alpha (IFN-alpha 3 MIU three times weekly)
Number of subjects: 40
Study: 1888646

Group type: EXPERIMENTAL
Intervention: Conventional carbamazepine (CBZ)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Controlled-release carbamazepine (CBZ-CR)
Number of subjects: 21
Study: 7114833

Group type: EXPERIMENTAL
Intervention: Dibekacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 0
Study: 30703349

Group type: COMPARATOR
Intervention: Epidural steroid injection (ESI) and education only
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Epidural steroid injection plus physical therapy (ESI+PT)
Number of subjects: 54
Study: 29532649

Group type: EXPERIMENTAL
Intervention: NMES
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focal vibration
Number of subjects: 0
Study: 26460229

Group type: EXPERIMENTAL
Intervention: 24-weeks group (discontinuation of risperidone or olanzapine at 24 weeks)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: 52-weeks group (continuation of risperidone or olanzapine for the full duration of the study)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: 52-weeks group
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Olanzapine patients in the 52-weeks group
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Risperidone patients in the 52-weeks group
Number of subjects: 159

Group type: COMPARATOR
Intervention: 0-weeks group
Number of subjects: 159

Group type: COMPARATOR
Intervention: 24-weeks group
Number of subjects: 159
Study: 24436491

Group type: EXPERIMENTAL
Intervention: Renal-specific oral nutrition supplement (RS-ONS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard recommended nutrition regime (CON)
Number of subjects: 62
Study: 22952598

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) 8 g/d (1.6 g/d EPA+DHA)
Number of subjects: 33

Group type: COMPARATOR
Intervention: High oleic sunflower oil (HOSO) 8 g/d
Number of subjects: 33
Study: 19544043

Group type: EXPERIMENTAL
Intervention: Splinting plus low-level laser therapy (SLLLT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Splinting (S)
Number of subjects: 45
Study: 17894323

Group type: EXPERIMENTAL
Intervention: Weight-based dosing of ribavirin (RBV)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Flat dosing of ribavirin (RBV)
Number of subjects: 362
Study: 14716191

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg
Number of subjects: 95

Group type: COMPARATOR
Intervention: Hormone Therapy (HT)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 11132612

Group type: EXPERIMENTAL
Intervention: Sildenafil (25-200 mg)
Number of subjects: 667

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 667
Study: 9113185

Group type: EXPERIMENTAL
Intervention: ALAGLN-group (alanyl-glutamine solution)
Number of subjects: 19

Group type: COMPARATOR
Intervention: AA-group (glucose and balanced amino acid solution)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study: 8469622

Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Isradipine 5 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 3951003

Group type: EXPERIMENTAL
Intervention: Cefoxitin (CX)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Clindamycin/Gentamicin (CG)
Number of subjects: 195
Study: 3277830

Group type: EXPERIMENTAL
Intervention: Treated gestational diabetes (group II)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Unsatisfactorily treated gestational diabetes (group III)
Number of subjects: 141
Study: 31179791

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30472919

Group type: EXPERIMENTAL
Intervention: Motivation group (motivation experimentally induced after the fatigue protocol)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no motivation induced after the fatigue protocol)
Number of subjects: 60
Study: 27474536

Group type: EXPERIMENTAL
Intervention: IPL exposure at 22, 34, 46 J/cm2 or triple stacking of 46 J/cm2
Number of subjects: 15

Group type: COMPARATOR
Intervention: Single solar‐simulated UVR exposure of 3 Standard Erythema Dose at 30 minutes or 24 hours after IPL
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Histology (H&E, Fontana‐Masson)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: mRNA-expression of p53
Number of subjects: 15
Study: 25499673

Group type: EXPERIMENTAL
Intervention: Outreaching stepped care program (Lust for Life)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 263
Study: 23442339

Group type: EXPERIMENTAL
Intervention: Intramedullary nail (MICRONAILTM)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Volar locking plate
Number of subjects: 62
Study: 21988742

Group type: EXPERIMENTAL
Intervention: C1-esterase inhibitor (200 U/kg intravenously)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 0
Study: 18317951

Group type: EXPERIMENTAL
Intervention: Magnesium treatment
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 167
Study: 16503705

Group type: EXPERIMENTAL
Intervention: Stepwise methadone induction (28, 56, then 84 mg/day)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Rapid methadone induction (28-84 mg on Days 1-6 to 56 mg/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Both groups (common contingency-management intervention)
Number of subjects: 34
Study: 12905979

Group type: EXPERIMENTAL
Intervention: Quadruple therapy (PPI + bismuth-based triple therapy)
Number of subjects: 3

Group type: COMPARATOR
Intervention: PPI-based triple therapy
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Quadruple therapy
Number of subjects: 3
Study: 11151436

Group type: EXPERIMENTAL
Intervention: Guided imaging (GI) relaxation techniques
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 86
Study: 9371898

Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray 20 mg
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray 10 mg
Number of subjects: 845

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 845
Study: 1376806

Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg
Number of subjects: 147

Group type: COMPARATOR
Intervention: Atenolol 100 mg
Number of subjects: 147
Study: 3920064

Group type: EXPERIMENTAL
Intervention: 200 mg Sorbinil
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 100 mg Sorbinil
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Topical 0.5 mg ophthalmic Sorbinil
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Oral Sorbinil
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Topical ophthalmic preparation
Number of subjects: 44
Study: 30644784

Group type: EXPERIMENTAL
Intervention: Telehealth Management of Diabetes Mellitus type 2 (T2DM)
Number of subjects: 8
Study: 29481486

Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Number of subjects: 159

Group type: COMPARATOR
Intervention: ATV + RTV plus FTC/TDF
Number of subjects: 159
Study: 27650868

Group type: EXPERIMENTAL
Intervention: BM32/20μg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: BM32/40μg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: BM32/10μg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: BM32
Number of subjects: 70
Study: 24859410

Group type: EXPERIMENTAL
Intervention: Ultracision
Number of subjects: 400

Group type: COMPARATOR
Intervention: Ligasure
Number of subjects: 400
Study: 22275126

Group type: EXPERIMENTAL
Intervention: Involvement of urinary incontinence nurse specialists in primary care
Number of subjects: 384

Group type: COMPARATOR
Intervention: Care-as-usual by general practitioners (GPs)
Number of subjects: 384
Study: 20617660

Group type: EXPERIMENTAL
Intervention: Voluntary management breathing control therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Psychological information about stress
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 50
Study: 18320396

Group type: EXPERIMENTAL
Intervention: Web-based decision aid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paper-based decision aid
Number of subjects: 0

Group type: COMPARATOR
Intervention: No pre-visit education (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Residents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Faculty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Residents and Faculty
Number of subjects: 0
Study: 15987851

Group type: EXPERIMENTAL
Intervention: EBF support given pre‐, peri‐, and postnatally (IG1)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: EBF support given only peri‐ and postnatally (IG2)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Nonbreast‐feeding health educational support (C)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: IG1 and IG2 combined
Number of subjects: 136
Study: 12847780

Group type: EXPERIMENTAL
Intervention: Millon Clinical Multiaxial Inventory‐‐Third Edition (MCMI‐III)
Number of subjects: 308
Study: 10632415

Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐E2 (50 microg/d)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐E2 (50 microg/d) + norethisterone acetate (250 microg/d)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy
Number of subjects: 13
Study: 8795747

Group type: EXPERIMENTAL
Intervention: Glaucoma treatment interventions (specifics not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled trials of glaucoma treatments (specifics not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current glaucoma clinical trials (specifics not provided)
Number of subjects: 0
Study: 1320966

Group type: EXPERIMENTAL
Intervention: 0.06/1000 allicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2.5% sodium bicarbonate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allium group (0.06/1000 allicin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 3082287

Group type: EXPERIMENTAL
Intervention: Mitomycin and Tegafur (group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PSK (group B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OK-432 (group C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PSK and OK-432 (group D)
Number of subjects: 0
Study: 30558918

Group type: EXPERIMENTAL
Intervention: Backward-downhill treadmill training
Number of subjects: 10

Group type: COMPARATOR
Intervention: Manual static stretching
Number of subjects: 10
Study: 27974670

Group type: EXPERIMENTAL
Intervention: SYNTAX score (SS)
Number of subjects: 457

Group type: COMPARATOR
Intervention: ACEF score
Number of subjects: 457
Study: 26437678

Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty (THA) in patients with ITP
Number of subjects: 11
Study: 23972110

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioural therapy (CBT)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 119
Study: 21410917

Group type: EXPERIMENTAL
Intervention: Peer rejection
Number of subjects: 740

Group type: COMPARATOR
Intervention: Best friend's externalizing problems
Number of subjects: 740
Study: 18234488

Group type: EXPERIMENTAL
Intervention: 800 mg/d of imatinib (400mg BID)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 400 mg/d of imatinib
Number of subjects: 0
Study: 16837138

Group type: EXPERIMENTAL
Intervention: Repithel (PVP-iodine in hydrogel, 3% concentration)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control (Jelonet-gauze only)
Number of subjects: 167
Study: 14671433

Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg)
Number of subjects: 30